arumakimig (MAS825) / Novartis - LARVOL DELTA

Managed Access Programs for MAS825, Arumakimig (clinicaltrials.gov) - P=N/A | N=0 | Temporarily Not Available | Sponsor: Novartis Pharmaceuticals

New trial • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: May 2023 ➔ Jul 2026 | Trial primary completion date: May 2023 ➔ Jul 2026

Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=130 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jul 2022 ➔ Jun 2023 | Trial primary completion date: May 2022 ➔ Aug 2022

Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial primary completion date: Aug 2022 ➔ Jun 2023

Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Novartis Pharmaceuticals | N=130 ➔ 200

Enrollment change • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Aug 2023 ➔ May 2023 | Trial primary completion date: Aug 2023 ➔ May 2023

Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=130 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Dec 2022 ➔ Jul 2022 | Trial primary completion date: Sep 2022 ➔ May 2022

Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=245 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial primary completion date: Oct 2026 ➔ Nov 2024

Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=248 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Sep 2026

Trial completion • Trial completion date • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: May 2021 ➔ Dec 2022 | Trial primary completion date: Jun 2020 ➔ Sep 2022

Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=130 | Recruiting | Sponsor: Novartis Pharmaceuticals | N=90 ➔ 130

Enrollment change • Dermatology • Hidradenitis Suppurativa • Immunology

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=248 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Dermatology • Hidradenitis Suppurativa • Immunology

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial

MAS NLRC4-GOF: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (clinicaltrials.gov) - P2 | N=17 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Apr 2032 ➔ Nov 2032

Trial completion date • Gastrointestinal Disorder • Inflammation • CDC42 • XIAP

MAS NLRC4-GOF: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (clinicaltrials.gov) - P2 | N=17 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Sep 2027 ➔ Apr 2032

Trial completion date • Gastrointestinal Disorder • Inflammation • CDC42 • XIAP

MAS NLRC4-GOF: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (clinicaltrials.gov) - P2 | N=17 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Feb 2029 ➔ Nov 2027

Trial completion date • Gastrointestinal Disorder • Inflammation • CDC42 • XIAP

MAS NLRC4-GOF: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (clinicaltrials.gov) - P2 | N=17 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jan 2031 ➔ Feb 2029

Trial completion date • Gastrointestinal Disorder • Inflammation • CDC42 • XIAP

MAS NLRC4-GOF: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (clinicaltrials.gov) - P2 | N=17 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastrointestinal Disorder • Inflammation • CDC42 • XIAP

MAS NLRC4-GOF: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (clinicaltrials.gov) - P2 | N=18 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Oct 2028 ➔ Jan 2031

Trial completion date • Gastrointestinal Disorder • Inflammation • CDC42 • XIAP

MAS NLRC4-GOF: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (clinicaltrials.gov) - P2 | N=8 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Dec 2027 ➔ Sep 2028 | Trial primary completion date: Oct 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Inflammation • CDC42 • XIAP

MAS NLRC4-GOF: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (clinicaltrials.gov) - P2 | N=8 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Apr 2027 ➔ Dec 2027 | Trial primary completion date: Feb 2024 ➔ Oct 2024

Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Immunology • Inflammation • CDC42 • XIAP

MAS NLRC4-GOF: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder • Immunology • Inflammation • CDC42 • XIAP